BAM
BLRX

Belpointe Asset Management’s BioLineRX BLRX Stock Holding History

Belpointe Asset Management’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-400
Closed -$14.2K – 911
2023
Q1 		$14.2K Hold
400
– – ﹤0.01% 2514
2022
Q4 		$9.44K Buy
+400
New +$11.9K ﹤0.01% 2646

Other funds holding BLRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return

Belpointe Asset Management's BLRX Position: Q2 2023 in Review

Belpointe Asset Management sold out of BioLineRX (BLRX) in Q2 2023, closing a stake of 400 shares — an estimated $14.2K sold.

Belpointe Asset Management first reported a position in BLRX in Q4 2022 and held it in 2 quarters. The position peaked at $14.2K in Q1 2023. 26 funds tracked by Wall St. Rank hold BLRX as of Q2 2023.

  • Belpointe Asset Management reported no remaining BioLineRX position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 400 BioLineRX shares in Q2 2023, an estimated $14.2K.
  • Belpointe Asset Management first reported a position in BioLineRX in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's BioLineRX position peaked at $14.2K in Q1 2023.
  • 26 funds tracked by Wall St. Rank held BioLineRX as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.